# MONOLISA™M Anti-HAV EIA 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

510(k) Number:   
510(k) Summary Report Date:

K 063318

April, 2007

MANUFACTURER INFORMATION

MANUFACTURER ADDRESS:

Bio-Rad $3 ,$ Boulevard Raymond Poincaré 92430 Marnes-la-Coquette, France

# TELEPHONE :

00 33 1 47 95 60 00

OWNER/OPERATOR :

Bio-Rad 3, Boulevard Raymond Poincaré 92430 Marnes-la-Coquette, France

8023061

OFFICIAL CORRESPONDENT ADDRESS :

Bio-Rad 3, Boulevard Raymond Poincaré 92430 Marnes-la-Coquette, France

# TELEPHONE:

00 33 1 47 95 60 00

Mrs. Sylvie Confida

TELEPHONE : FAX :

00 33 1 47 95 61 38   
00 33 1 47 95 62 42

CLASSIFICATION INFORMATION   
CLASSIFICATION NAME:   
COMMON NAME:   
PRODUCT TRADE NAME:   
DEVICE CLASS :

HepatitisATeoal Total Antiody to epati MONOLISA™ Anti-HAV EIA Class II LOL

CLASSIFICATION PANEL : Immunology and Microbiology Devices REGULATION NUMBER : 21 CFR 866.3310

# LEGALLY MARKETED EQUIVALENT (SE) DEVICE

DiaSorin ETI-AB-HAVK PLUS PMA Number : P890019 Decision Date : 12/12/2005

# DEVICE DESCRIPTION

The MONOLISA™ Anti-HAV EIA is an enzyme immunoassay (competitive assay format) for the detection of total antibodies to Hepatitis A virus. In the assay procedure, patient specimens, a calibrator and controls are incubated with HAV antigen in microwells that have been coated with mouse monoclonal anti-Hepatitis A antibodies. Antibodies to HAV present in a specimen or control will complex with the HAV antigen reagent and with antibodies coated on the microwells. Excess sample and HAV Viral antigen reagent are removed by a wash step. The conjugate (containing horseradish peroxidase-labeled mouse monoclonal antibody to HAV) is subsequently added to the microwells and incubated. The conjugate binds to the HAV antigen bound to the microwell in the absence of antibodies to HAV from the specimen. Excess conjugate is removed by a wash step, and a TMB Chromogen / Substrate solution is added to the microwells and allowed to incubate. If a sample does not contain anti-HAV antibodies, the bound enzyme (HRP) causes the colorless tetramethylbenzidine (TMB) in the Chromogen solution to change to blue. The blue color turns yellow after the addition of a Stopping Solution. If a sample contains antiHAV antibodies, the Chromogen / Substrate Solution in the well remains colorless during the substrate incubation, and after the addition of the Stopping Solution. The color intensity is measured spectrophotometrically.

Absorbance value readings for patient specimens are compared to the Cutoff value determined by the mean of the Calibrator absorbance values.

# KIT COMPONENTS

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>R1 Microwell Strip Plates</td><td rowspan=1 colspan=1>Two (2) x 12 strips of 8 wells coated with monoclonal anti-HAVantibodies.</td></tr><tr><td rowspan=1 colspan=1>R2 Wash SolutionConcentrate (30x)</td><td rowspan=1 colspan=1>One (1) 120 mL bottle, Tris-buffer containing NaCl and Tween 20.</td></tr><tr><td rowspan=1 colspan=1>CO Negative Control</td><td rowspan=1 colspan=1>One (1) 1.5 mL vial, containing human serum, negative for total anti-HAV antibodies, HBs antigen, anti-HCV antibodies and anti-HIV-1/HIV-2 antibodies. Preservatives : Sodium azide (&lt; 0.1%) and Proclin™300 (0.25%).</td></tr><tr><td rowspan=1 colspan=1>C1 Positive Control</td><td rowspan=1 colspan=1>One (1) 1.5 mL vial, containing human serum, positive for anti-HAVantibodies and negative for HBs antigen, anti-HCV antibodies andanti-HIV-1/HIV-2 antibodies, diluted in human serum pool negative foranti-HAV antibodies. Preservatives : Sodium azide (&lt; 0.1%) andProclin™ 300 (0.25%).</td></tr><tr><td rowspan=1 colspan=1>C2 Calibrator</td><td rowspan=1 colspan=1>Two (2) x 1.5 mL vials, containing human serum, positive for anti-HAVantibodies, and negative for HBs Antigen, anti-HCV antibodies andanti-HIV-1/HIV-2 antibodies, diluted in human serum pool negative foranti-HAV antibodies. Preservatives : Sodium azide (&lt; 0.1%) andProclin™ 300 (0.25%).</td></tr><tr><td rowspan=1 colspan=1>R6 HAV Viral Antigen</td><td rowspan=1 colspan=1>Two (2) x 14 mL bottles, inactivated HAV virus in Tris buffer containingproteins and sample indicator dye. Preservative : Proclin™ 300 (0.1%).</td></tr><tr><td rowspan=1 colspan=1>R7 Conjugate</td><td rowspan=1 colspan=1>Two (2) x 14 mL bottles, conjugate (Peroxidase labeled mousemonoclonal antibody to HAV) in Tris buffer containing proteins,detergent and sample indicator dye. Preservative : Proclin™ 300(0.1%).</td></tr><tr><td rowspan=1 colspan=1>R8 Substrate Buffer</td><td rowspan=1 colspan=1>One (1) 120 mL bottle, containing Hydogen Peroxide, citric acid /sodium acetate buffer and Dimethylsulfoxide (DMSO).</td></tr><tr><td rowspan=1 colspan=1>R9 Chromogen (11x)</td><td rowspan=1 colspan=1>One (1) 12 mL bottle, containing Tetramethylbenzidine (TMB).</td></tr><tr><td rowspan=1 colspan=1>R10 Stopping Solution</td><td rowspan=1 colspan=1>One (1) 120 mL bottle, containing 1 N H2SO4.</td></tr><tr><td rowspan=1 colspan=1>Plate sealers</td><td rowspan=1 colspan=1>Eight (8) clear plastic sealers.</td></tr></table>

# INTENDED USE

The MONOLISA™ anti-HAV EIA is an in vitro enzyme immunoassay kit intended for use in the qualitative detectionf total antibodies anti-HAV gGand IgM)to HepatitisAvirus anti-HAV) human (adult and pediatric) serum or plasma (EDTA, Heparin, Citrate, ACD.

This assay is not intended for screening blood or solid or soft tissue donors.

# INDICATIONS FOR USE

The MONOLISA™ anti-HAV EIA is indicated for use as an aid in the diagnosis of acute or past Hepatitis A Virus (HAV) infection or as anaid in the identification of HAV-susceptible individuals for vaccination. However, any diagnosis should take into consideration the patient's clinical history and symptoms, as well as serological data.

Assy performance characteristic hav ot been etablished for immunocompromi o immunosuppressed patients, and core blood or neonatal specimens.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the MONOLISA™ Anti-HAV EIA kit and the predicate device ETI-AB-HAVK PLUS.

Table 1: Similarities between kit components and materials   

<table><tr><td rowspan=1 colspan=1>Similarities inComponents / Materials</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVEIACatalog# 72496</td><td rowspan=1 colspan=1>ETI-AB-HAVK PLUSCatalog# P001926</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Microplate wells coated withmouse Monoclonal anti-HAVantibodies.</td><td rowspan=1 colspan=1>Microplate wells coated withmouse Monoclonal anti-HAVantibodies.</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Peroxidase-labeled mousemonoclonal antibody to HAV.</td><td rowspan=1 colspan=1>Peroxidase-labeled mousemonoclonal antibody to HAV.</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>Human serum, negative fortotal anti-HAV antibodies.</td><td rowspan=1 colspan=1>Human serum/plasma,negative for total anti-HAVantibodies.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Human serum, positive foranti-HAV antibodies, dilutedin human serum poolnegative for anti-HAVantibodies.</td><td rowspan=1 colspan=1>Human serum/plasma,containing anti-HAVantibodies.</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>Human serum, positive foranti-HAV antibodies, dilutedin human serum poolnegative for anti-HAVantibodies.</td><td rowspan=1 colspan=1>Human serum/plasma,reactive for anti-HAVantibodies.</td></tr><tr><td rowspan=1 colspan=1>Chromogen</td><td rowspan=1 colspan=1>Tetramethylbenzidine (TMB)</td><td rowspan=1 colspan=1>Tetramethylbenzidine (TMB)</td></tr></table>

# BIO RAD

<table><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>Hydrogen Peroxide</td><td rowspan=1 colspan=1>Hydrogen Peroxide</td></tr><tr><td rowspan=1 colspan=1>Washing Solution</td><td rowspan=1 colspan=1>Concentrated bufferedsolution with Tween 20.</td><td rowspan=1 colspan=1>Concentrated bufferedsolution with detergents.</td></tr></table>

Table 2: Differences between kit components and materials   

<table><tr><td rowspan=1 colspan=1>Differences inComponents / Materials</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVEIACatalog# 72496</td><td rowspan=1 colspan=1>ETI-AB-HAVK PLUSCatalog# P001926</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Ready-to-use.</td><td rowspan=1 colspan=1>To be diluted.</td></tr><tr><td rowspan=1 colspan=1>Incubation buffer</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>Buffer, containing proteinstabilizers and an inert bluedye.</td></tr><tr><td rowspan=1 colspan=1>Viral Antigen / NeutralizingSolution</td><td rowspan=1 colspan=1>Tris-buffer, containinginactivated HAV-virus,proteins and sampleindicator dye.</td><td rowspan=1 colspan=1>Buffer, containing HAV,human serum/plasma andprotein stabilizers.</td></tr><tr><td rowspan=1 colspan=1>Stopping Solution</td><td rowspan=1 colspan=1>1N H2SO4.</td><td rowspan=1 colspan=1>0.4N H2SO4.</td></tr></table>

Table 3: Similarities between kits with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities in Functionand Use</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVEIACatalog# 72496</td><td rowspan=1 colspan=1>ETI-AB-HAVK PLUSCatalog# P001926</td></tr><tr><td rowspan=1 colspan=1>Test Method</td><td rowspan=1 colspan=1>EIA (competitive assayformat)</td><td rowspan=1 colspan=1>EIA (competitive test)</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>96-well microplate</td><td rowspan=1 colspan=1>96-well microplate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Assay for the qualitativedetection of total anti-HAVantibodies in human serum orplasma.</td><td rowspan=1 colspan=1>Assay for the qualitativedetection of total anti-HAVantibodies in human serum orplasma.</td></tr><tr><td rowspan=1 colspan=1>Required sample volume</td><td rowspan=1 colspan=1>50 μl</td><td rowspan=1 colspan=1>50 μl</td></tr><tr><td rowspan=1 colspan=1>Specimen StorageRequirements</td><td rowspan=1 colspan=1>Samples may be stored at2-8 °C for up to 24 hours.</td><td rowspan=1 colspan=1>Samples may be stored at2-8 °C for up to 24 hours.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Referenced to WHO Anti-Hepatitis A Immunoglobulin2d International Standard.</td><td rowspan=1 colspan=1>Referenced to WHO Anti-Hepatitis A Immunoglobulin2nd International Standard.</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>Dual wavelength reading at450 nm and 615/630 nm.</td><td rowspan=1 colspan=1>Dual wavelength reading at450 nm and 630 nm.</td></tr><tr><td rowspan=1 colspan=1>Interpretation of results</td><td rowspan=1 colspan=1>Obtained absorbance valuereadings for patientspecimens are compared tothe cut-off value determinedby the mean of the calibratorabsorbance values.</td><td rowspan=1 colspan=1>Obtained absorbancereadings for patientspecimens are compared to acut-off value determined fromthe mean of the calibratorabsorbance values.</td></tr></table>

Table 4: Differences between kits with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences in Functionand Use</td><td rowspan=1 colspan=1>MONOLISATM anti-HAV EIACatalog# 72496</td><td rowspan=1 colspan=1>ETI-AB-HAVK PLUSCatalog# P001926</td></tr><tr><td rowspan=1 colspan=1>SpectrophotometricVerification of Sample andReagent Pipeting</td><td rowspan=1 colspan=1>Possible (but optional)</td><td rowspan=1 colspan=1>NA</td></tr></table>

# EXPECTED VALUES

# Healthy individuals

The expected results of the MONOLISA™ Anti-HAV EIA assay were determined in presumably healthy individuals from the Mid-west US (St Louis, Missouri), the Western US (California and Washington) and from Europe (Parma, Italy).

In the Mid-west, the population was $5 5 \%$ female and $45 \%$ male, with ages ranging from 1 to 96 years. $48 \%$ (134) were pediatric specimens.

The majority of the subjects were White/Caucasian $( 6 4 \% )$ , and $32 \%$ were black or African American; for $4 \%$ data were not available.

In this study, $41 \%$ were found reactive for Anti-HAV total antibodies, and $5 7 \%$ were found nonreactive.

In the Western US, $73 \%$ were from California, $2 7 \%$ were from Washington. The population was $56 \%$ female and $44 \%$ male, and their ages ranged from 15 to 90 years.

In this population, $3 8 \%$ were found reactive or Anti-HAV total antibodies, and $6 2 \%$ were found nonreactive.

In Europe, the population was $50 \%$ female and $50 \%$ male, with ages ranging from 18 to 87 years. In this group, $69 \%$ were found reactive for Anti-HAV total antibodies and $31 \%$ were found nonreactive.

presented below (Tables 5, 6 and 7).

Table 5: Expected Results for MONOLISA™M Anti-HAV EIA in subjects from the Midwest US (N= 280)   

<table><tr><td colspan="10">MONOLISAT Anti-HAV EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt; 10</td><td>Female</td><td>10</td><td>28.6%</td><td>0</td><td>N/A</td><td>25</td><td>71.4%</td><td>35</td></tr><tr><td rowspan="3">10 -19 :</td><td>Male</td><td>7</td><td>18.4%</td><td>2</td><td>5.3%</td><td>29</td><td>76.3%</td><td>38</td></tr><tr><td>Female</td><td>14</td><td>36.8%</td><td>2</td><td>5.3%</td><td>22</td><td>57.9%</td><td>38</td></tr><tr><td>Male</td><td>9</td><td>39.1%</td><td>0</td><td>N/A</td><td>14</td><td>60.9%</td><td>23</td></tr><tr><td rowspan="2">20- 29</td><td>Female</td><td>3</td><td>60.0%</td><td>0</td><td>N/A</td><td>2</td><td>40.0%</td><td>5</td></tr><tr><td>Male</td><td>3</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>3</td></tr><tr><td rowspan="2">30 -39</td><td>Female</td><td>5</td><td>50.0%</td><td>0</td><td>N/A</td><td>5</td><td>50.0%</td><td>10</td></tr><tr><td>Male</td><td>3</td><td>33.3%</td><td>0</td><td>N/A</td><td>6</td><td>66.7%</td><td>9</td></tr><tr><td rowspan="2">40 -49</td><td>Female</td><td>3</td><td>23.1%</td><td>0</td><td>N/A</td><td>10</td><td>76.9%</td><td>13</td></tr><tr><td>Male</td><td>4</td><td>50.0%</td><td>0</td><td>N/A</td><td>4</td><td>50.0%</td><td>8</td></tr><tr><td rowspan="2">50 -59</td><td>Female</td><td>10</td><td>55.6%</td><td>0</td><td>N/A</td><td>8</td><td>44.4%</td><td>18</td></tr><tr><td>Male</td><td>8</td><td>47.1%</td><td>0</td><td>N/A</td><td>9</td><td>52.9%</td><td>17</td></tr><tr><td rowspan="2">60 -69</td><td>Female</td><td>8</td><td>57.1%</td><td>0</td><td>N/A</td><td>6</td><td>42.9%</td><td>14</td></tr><tr><td>Male</td><td>4</td><td>30.8%</td><td>0</td><td>N/A</td><td>9</td><td>69.2%</td><td>13</td></tr><tr><td rowspan="2">70-79</td><td>Female</td><td>6</td><td>66.7%</td><td>1</td><td>11.1%</td><td>2</td><td>22.2%</td><td>9</td></tr><tr><td>Male</td><td>5</td><td>83.3%</td><td>0</td><td>N/A</td><td>1</td><td>16.7%</td><td>6</td></tr><tr><td rowspan="2">80-89</td><td>Female</td><td>9</td><td>69.2%</td><td>0</td><td>N/A</td><td>4</td><td>30.8%</td><td>13</td></tr><tr><td>Male</td><td>3</td><td>50.0%</td><td>0</td><td>N/A</td><td></td><td>50.0%</td><td>6</td></tr><tr><td rowspan="2">&gt;=90</td><td rowspan="2">Female Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>3</td><td></td><td></td></tr><tr><td>1</td><td>50.0%</td><td>0</td><td>N/A</td><td>0 1</td><td>N/A</td><td>0</td></tr><tr><td colspan="2">Total</td><td>115 -</td><td>41.1%</td><td>5</td><td>1.8%</td><td>160</td><td>50.0% 57.1%</td><td>2 280</td></tr></table>

Table 6: Expected Results for MONOLISA™M Anti-HAV EIA in subjects from the Western US (N= 245)   

<table><tr><td colspan="9">MONOLISATM Anti-HAV EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt;19</td><td>Female</td><td>3</td><td>60.0%</td><td>0</td><td>N/A wel. ma</td><td>2</td><td>40.0%</td><td>5</td></tr><tr><td rowspan="2">20- 29</td><td>Male</td><td>1</td><td>20.0%</td><td>0</td><td>N/A</td><td>4</td><td>80.0%</td><td>5</td></tr><tr><td>Female</td><td>11</td><td>42.3%</td><td>0</td><td>N/A</td><td>15</td><td>57.7%</td><td>26</td></tr><tr><td rowspan="2">30 -39</td><td>Male</td><td>5</td><td>20.8%</td><td>0</td><td>N/A</td><td>19</td><td>79.2%</td><td>24</td></tr><tr><td>Female</td><td>10</td><td>50.0%</td><td>0</td><td>N/A</td><td>10</td><td>50.0%</td><td>20</td></tr><tr><td rowspan="2">40 -49</td><td>Male Female</td><td>5</td><td>27.8%</td><td>0</td><td>N/A</td><td>13</td><td>72.2%</td><td>18</td></tr><tr><td></td><td>6</td><td>33.3%</td><td>0</td><td>N/A</td><td>12</td><td>66.7%</td><td>18</td></tr><tr><td rowspan="2">50 -59</td><td>Male Female</td><td>10</td><td>45.5%</td><td>0</td><td>N/A</td><td>12</td><td>54.5%</td><td>22</td></tr><tr><td></td><td>15</td><td>38.5%</td><td>1</td><td>2.6%</td><td>23</td><td>59.0%</td><td>39</td></tr><tr><td rowspan="2">60 -69</td><td>Male</td><td>5</td><td>23.8%</td><td>0</td><td>N/A</td><td>16</td><td>76.2%</td><td>21</td></tr><tr><td>Female</td><td>6</td><td>50.0%</td><td>0</td><td>N/A :</td><td>6</td><td>500%</td><td>12</td></tr><tr><td rowspan="2">70-79</td><td>Male</td><td>4</td><td>33.3%</td><td>0</td><td>N/A 1</td><td>8</td><td>66.7%</td><td>12</td></tr><tr><td>Female</td><td>1</td><td>11.1%</td><td>0</td><td>N/A</td><td>8</td><td>88.9%</td><td>9</td></tr><tr><td rowspan="2">80-89</td><td>Male</td><td>1</td><td>50.0%</td><td>0</td><td>N/A</td><td>1</td><td>50.0%</td><td>2</td></tr><tr><td>Female</td><td>6</td><td>100%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>6</td></tr><tr><td rowspan="3">&gt;=90</td><td>Male</td><td>3</td><td>75.0%</td><td>0</td><td>N/A</td><td>1</td><td>25.0%</td><td>4</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Unknown</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td colspan="2">Total</td><td>92</td><td>37.6%</td><td>1</td><td>0.4%</td><td>152</td><td>62.0%</td><td>245</td></tr></table>

# BIO RAD

Table 7: Expeced Results or MONOLISA™ Anti-HAV EIA in subjects from Italy, Europe (N= 285)   

<table><tr><td colspan="9">MONOLISA™ Anti-HAV EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive :</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt; 19</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td></td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td rowspan="2">20-29</td><td>Female</td><td>1</td><td>33.3%</td><td>0</td><td>N/A</td><td>2</td><td>66.7%</td><td>3</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>2</td><td>100.0%</td><td>2</td></tr><tr><td rowspan="3">30-39 40-49</td><td>Female</td><td>1</td><td>14.3%</td><td>0</td><td>N/A</td><td>6</td><td>85.7%</td><td>7</td></tr><tr><td>Male</td><td>2</td><td>28.6%</td><td>0</td><td>N/A</td><td>5</td><td>71.4%</td><td>7</td></tr><tr><td>Female</td><td>7</td><td>33.3%</td><td>0</td><td>N/A</td><td>14</td><td>66.7%</td><td>21</td></tr><tr><td rowspan="2">50-59</td><td>Male</td><td>3</td><td>15.8%</td><td>0</td><td>N/A</td><td>16</td><td>84.2%</td><td>19</td></tr><tr><td>Female</td><td>10</td><td>45.5%</td><td>0</td><td>N/A</td><td>12</td><td>54.5%</td><td>22</td></tr><tr><td rowspan="2">60-69</td><td>Male</td><td>14</td><td>51.9%</td><td>0</td><td>N/A</td><td>13</td><td>48.1%</td><td>27</td></tr><tr><td>Female</td><td>37</td><td>86.0%</td><td>0</td><td>N/A</td><td>6</td><td>14.0%</td><td>43</td></tr><tr><td rowspan="2">70-79</td><td>Male</td><td>23</td><td>85.2%</td><td>0</td><td>N/A</td><td>4</td><td>14.8%</td><td>: 27</td></tr><tr><td>Female</td><td>31</td><td>96.9%</td><td>0</td><td>N/A</td><td>1</td><td>3.1%</td><td>32</td></tr><tr><td rowspan="2">80-89 1</td><td>Male</td><td>32</td><td>86.5%</td><td>0</td><td>N/A</td><td>5</td><td>13.5%</td><td>37</td></tr><tr><td>Female</td><td>13</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>13</td></tr><tr><td rowspan="2">1 Total</td><td>Male</td><td>23</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>23</td></tr><tr><td></td><td>197</td><td>69.1%</td><td>0</td><td>N/A</td><td>88</td><td>30.9%</td><td>285</td></tr></table>

# Adult Subjects At High Risk For Viral Hepatitis:

Expected results of asymptomatic prospective high-risk subjects, determined from a multi-center study in the US and in Europe, are reported in the following tables.

A total of 230 US subjects were at high risk for viral hepatitis including intravenous drug users $( N = 5 5 )$ , homosexual males $( N { = } 1 5$ , sex workers $( N = 3 9$ prison history $( N = 9 2 )$ , high-risk sex partners $( N = 2 5 )$ , and high-risk occupation/health care workers $( N = 4 )$ . Many had more than 1 high-risk behavior or risk factor. Subjects were from Los Angeles, $\mathsf { C A } ,$ $( 8 6 . 5 \% )$ , Santa Ana, CA $( 4 . 3 \% )$ , or Miami, FL $( 9 . 1 \% )$ . The group was Caucasian $( 7 . 4 \% )$ Black or African American $( 7 4 . 3 \% ) ,$ Hispanic or Latino $( 1 5 . 2 \% )$ , Asian $( 0 . 4 \% )$ Native Hawaian or other Pacific Islander $( 0 . 4 \% ) ,$ and American Indian or Alaska native $( 0 . 9 \% )$ , with the remaining $( 1 . 3 \% )$ represented by multiple ethnic groups.

Of these subjects, $8 1 \%$ were male and $1 9 \%$ were female, and they ranged in age from 18 to70 years (mean age of 45). The data are reported in Table 8.

per iHAVreivreults w LnAVAhi hiis asymptomatic population was $5 3 \%$ .

The European group $( N = 6 2 )$ was $8 7 \%$ male and $1 3 \%$ female, and ranged in age from 21 to 75 years (mean age of 40). It consisted of intravenous drug users (30), subjects who had clotting factor disorders (7) and MSM patients (25). The data are reported in Table 9.

asymptomatic population was $45 \%$ .

Table 8: Expected results for MONOL $\pmb { \tau } \pmb { S } \pmb { A } ^ { T M }$ AnHAVEIA n heUS High Risk G Viral Hepatitis A $( N = 2 3 0 )$   

<table><tr><td colspan="9">MONOLISAT Anti-HAV EIA</td></tr><tr><td>Age</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>Range &lt; 19</td><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td rowspan="3">20-29</td><td>Female</td><td>1</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td></tr><tr><td>Male</td><td>1</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td></tr><tr><td>Female Male</td><td>1</td><td>33.3%</td><td>0</td><td>N/A</td><td>2</td><td>66.7%</td><td>3</td></tr><tr><td>30-39</td><td>Female</td><td>1 4</td><td>50.0% 57.1%</td><td>0</td><td>N/A</td><td>1</td><td>50.0%</td><td>2</td></tr><tr><td rowspan="3">40-49</td><td>Male</td><td></td><td></td><td>0</td><td>N/A</td><td>3</td><td>42.9%</td><td>7</td></tr><tr><td>Female</td><td>12</td><td>33.3%</td><td>0</td><td>N/A</td><td>24</td><td>66.7%</td><td>36</td></tr><tr><td></td><td>15</td><td>62.5%</td><td>0</td><td>N/A</td><td>9</td><td>37.5%</td><td>24</td></tr><tr><td rowspan="2">50-59</td><td>Male</td><td>37</td><td>43.5%</td><td>1</td><td>1.2%</td><td>47</td><td>55.3%</td><td>85</td></tr><tr><td>Female</td><td>6</td><td>85.7%</td><td>0</td><td>N/A</td><td>1</td><td>14.3%</td><td>7</td></tr><tr><td rowspan="2">60-69</td><td>Male</td><td>31</td><td>60.8%</td><td>1</td><td>2.0%</td><td>19</td><td>37.3%</td><td>51</td></tr><tr><td>Female</td><td>1</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td></tr><tr><td rowspan="2">70-79</td><td>Male</td><td>9</td><td>90.0%</td><td>0</td><td>N/A</td><td>1</td><td>10.0%</td><td>10</td></tr><tr><td>Female Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td colspan="2">Total</td><td>2 121</td><td>100.0% 52.6%</td><td>0 2</td><td>N/A 0.9%</td><td>0 107</td><td>N/A 46.5%</td><td>2 230</td></tr></table>

# BIO RAD

Table 9: Expected results for MONOLISA™ Anti-HAV EIA in the European High Risk Group for Viral Hepatitis A $( N { = } E 2 )$ EY   

<table><tr><td colspan="9">MONOLISATM Anti-HAV EIA</td></tr><tr><td>Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td></td><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td rowspan="2">&lt; 19</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Male 1</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td rowspan="2">20-29</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>5</td><td>100.0%</td><td>5</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>11</td><td>100.0%</td><td>11</td></tr><tr><td rowspan="2">30-39</td><td>Female</td><td>1</td><td>50.0%</td><td>0</td><td>N/A</td><td>1</td><td>50.0%</td><td>2</td></tr><tr><td>Male</td><td>5</td><td>35.7%</td><td>0</td><td>N/A</td><td>9</td><td>64.3%</td><td>14</td></tr><tr><td rowspan="2">40-49</td><td>Female Male</td><td>1</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td></tr><tr><td></td><td>9</td><td>64.3%</td><td>0</td><td>N/A</td><td>5</td><td>35.7%</td><td>14</td></tr><tr><td rowspan="2">50-59</td><td>Female Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td></td><td>9</td><td>81.8%</td><td>0</td><td>N/A</td><td>2</td><td>18.2%</td><td>11</td></tr><tr><td rowspan="2">60-69</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Male</td><td>1</td><td>50.0%</td><td>0</td><td>N/A</td><td>1</td><td>50.0%</td><td>2</td></tr><tr><td rowspan="2">70-79</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Male Female</td><td>2</td><td>100.0%</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>2</td></tr><tr><td rowspan="2" colspan="2">&gt;80</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td colspan="2">Male Total</td><td>28</td><td>45.2%</td><td>0</td><td>N/A</td><td>34</td><td>54.8%</td><td>62</td></tr></table>

# PERFORMANCE CHARACTERISTICS

# Clinical performance

A multi-center prospective and retrospective study was conducted to evaluate the clinical performance of the MONOLISA™ Anti-HAV EIA assay among individuals with signs or symptoms and those at high risk of Hepatitis infection. Specimens were collected in 3 different geographical areas: 404 specimens were collected in the US and 928 were collected in Europe (France and Italy).

The US population consisted of 174 subjects with signs and symptoms of Hepatitis.

Of these, $60 \%$ were male and $40 \%$ were female, and they ranged in age from 17 to 72 years (mean age of 38). The group was Caucasian $( 1 3 . 2 \% )$ Black or African American $( 4 . 6 \% ) _ { i }$ Hispanic or Latino $( 2 . 9 \% )$ , and Asian $( 4 1 . 9 \% )$ , with $1 . 1 \%$ represented by multiple ethnic groups. The remaining $3 6 . 8 \%$ were unknown. Among these 174 subjects, 23 $( 1 3 . 2 \% )$ were pediatric samples.

The 230 subjects from the high-risk group for Hepatitis A include intravenous drug users $\mathsf { N } =$ 55), homosexual males $( N { = } 1 5 )$ , sex workers $( N = 3 9 )$ , prison history $( N = ~ 9 2 )$ ,high-risk sex partners $( N = 2 5 )$ , and high-risk occupation/health care workers $( N { = } 4 )$ . Many had more than 1 high-risk behavior or risk factor. The group was Caucasian $( 7 . 4 \% )$ , Black or African American $( 7 4 . 3 \% ) _ { i }$ ,Hispanic or Latino $( 1 5 . 2 \% )$ ,Asian $( 0 . 4 \% )$ , Native Hawaiian or other Pacific Islander $( 0 . 4 \% ) ,$ and American Indian or Alaska native $( 0 . 9 \% ) ,$ ,with the remaining $( 1 . 3 \% )$ represented by multiple ethnic groups. Of these, $8 1 \%$ were male and $1 9 \%$ were female, and they ranged in age from 18 to 70 years (mean age of 45). Among these 230 subjects, 2 $( 0 . 9 \% )$ were pediatric samples.

The European population consisted of 252 specimens collected from patients with signs and symptoms of Hepatitis. Of these, $5 1 \%$ were male and $4 9 \%$ were female, and they ranged in age from 1 to 105 years (mean age of 53).

Sixty-two (62) specimens were collected from a population at high risk for hepatitis composed of intravenous drug users (30), subjects who had clotting factor disorders (7) and MSM patients (25). The group was $8 7 \%$ male and $1 3 \%$ female, and ranged in age from 21 to 75 years (mean age of 40).

Three hundred and forty five (345) specimens were from an asymptomatic hospitalized population. Of these, $51 \%$ were male and $49 \%$ were female, and they ranged in age from 18 to 87 years (mean age of 59).

Thirty our (34) speciens were from healthcare workers for HAV pre-vaccination screeig).   
One hundred and fifty one (151) patients had recovered HAV infection.

Among these 844 european samples, 35 $( 4 . 1 \% )$ were from pediatric subjects.

# Vaccinated subjects:

Sixty-two (62) pre- and post-vaccination samples from 38 individuals were tested.Fourteen (14) individuals were enrolled in a vaccination program. They received the TWINRIx® vaccine, a combined Hepatitis A and Hepatitis B vaccine from GlaxoSmithKline. A pre-vaccination sample was collected the day of the first vaccination dose. A second sample was collected before the second vaccination dose was injected (one month after the first dose). A third dose of vaccine was scheduled 6 months after the first injection. The sample after the third vaccination dose was not available.

Twenty (20) samples were collected from 10 subjects, aged 24 to 45 years, who had received the HAVR® ch ubjeteceiHAVR®ava etit from GlaxoSmithKline, in a two-dose schedule (at 0 and 6 to 12 months). For each subject, a preand a post-vaccination specimen was obtained. All post-vaccination samples were obtained 4 weeks after vaccination.

Fourteen (14) purchased post-vaccination samples were tested; 8 were from individuals A®   e

Percent Agreement

T ultbta wih MOL™ntiHAV A we cad wit he results b using the comparative assay.

The positive and negative percent agreements and the $9 5 \%$ exact confidence between NOLISA™ Anti-HAV EIA and the comparative assay were calculated.

penou

A  HA - Specimens that were borderline with the comparative assay and nonreactive with MoNOLISA™ Anti-HAV EIA were considered as false negatives or MONOLISA™ Anti-HAV EIA.

The results obtained with the US specimens and with the European specimens are presented in the following tables.

Table 10: MONOLISA™ Anti-HAV EIA versus the comparative assay Results in the US Population $( N = 4 0 4 )$   

<table><tr><td rowspan=3 colspan=1>Subject category</td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparative assayBorderline</td><td rowspan=1 colspan=3>Comparative assay:Negative</td><td rowspan=3 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>MONOLISATMAnti-HAV EIA</td><td rowspan=1 colspan=3>MONOLISAT Anti-HAVEIA</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIA</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=1 colspan=1>Subjects with signsand symptoms</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>174</td></tr><tr><td rowspan=1 colspan=1>Subjects with highrisk for Hepatitis</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>230</td></tr><tr><td rowspan=1 colspan=1>Tota!</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>$3 b}$</td><td rowspan=1 colspan=1>1d</td><td rowspan=1 colspan=1>1c</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4a</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>404</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td><td rowspan=1 colspan=1>Negative percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>98,8%(237/240)</td><td rowspan=1 colspan=1>96.4 - 99.7</td><td rowspan=1 colspan=1>92.6%(151/163)</td><td rowspan=1 colspan=1>87.5 - 96.1</td></tr></table>

R Reactive, NR : Nonreactive, BRD: Borderline the Borderline results with MONOLISA™ Anti-HAV EIA were considered as false positives. sha w B i t ss   OLA considered as false positives with MONOLISA™m Anti-HAV EIA. considered as false negative with MONOLISA™ Anti-HAV EIA. at w o i oeA  e  y w included in the negative agreement or the positive agreement calculations.

# BIO RAD

Table 11: Comparison of Results for MONOLISA™M Anti-HAV EIA versus the comparative assay in the European Population $( N = 8 4 4 )$ EY   

<table><tr><td rowspan=3 colspan=1>Subjectcategory</td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparativeassay:Borderline</td><td rowspan=1 colspan=3>Comparativeassay:Negative</td><td rowspan=3 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIA</td><td rowspan=1 colspan=3>MONOLISA™MAnti- HAV EIA</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIA</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=1 colspan=1>Generalhospitalizedpopulation</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>345</td></tr><tr><td rowspan=1 colspan=1>Sign /Symptoms ofHepatitis</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>252</td></tr><tr><td rowspan=1 colspan=1>Subjectswih highrisk forHepatitis</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>Healthcareworkers</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Infected/recoveredHAV</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>610</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>2d</td><td rowspan=1 colspan=1>1c</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1$</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>844</td></tr></table>

<table><tr><td></td><td>Positive percent agreement</td><td>95% Exact Confidence interval</td><td>Negative percent agreement</td><td>95% Exact Confidence interval</td></tr><tr><td>Total</td><td>99.7% (610/612)</td><td>98.8  99.9</td><td>98.7% (227/230)</td><td>96.2 - 99.7</td></tr></table>

RReactive, NR : Nonreactive; BRD : Borderline he Borderline result with MONOLISA™ Anti-HAV EIA was considered as false positive peen hat was Bordere with e paativ assy n reacv wi NOLAnHAV IA was considered as false positive with MONOLISA™ Anti-HAV EIA. ov LA considered as false negative with MONOLISA™m Anti-HAV EIA. u A calculation of the negative agreement or the positive agreement.

# Acute HAV Infection:

Among the retrospective samples, 84 were from subjects with a medical history and laboratory results indicative of acute Hepatitis A. The subjects included $56 \%$ male, $3 7 \%$ female; the gender was not available for 7%. The mean age was 21, and subjects ranged from 1 to 55 years. Among them 39 were pediatric subjects.

The results are presented in the following table:

Table 12: Comparison of Results for MONOLISA™M Anti-HAV EIA versus the comparative assay on Acute HAv infection in the adult and pediatric European Population $( N = 8 4 )$ :   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparative assay:Borderline</td><td rowspan=1 colspan=3>Comparative assay:Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=3>MONOLISA™M Anti-HAV EIAR     BRD    NR</td><td rowspan=1 colspan=2>MONOLISATM Anti-HAV EIA</td><td rowspan=2 colspan=1>NR</td><td rowspan=2 colspan=1>R</td><td rowspan=2 colspan=1>MONOLISATM Anti-HAV EABRD</td><td rowspan=2 colspan=1>NR</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td></tr><tr><td rowspan=1 colspan=1>Adults</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>.45</td></tr><tr><td rowspan=1 colspan=1>Pediatrics</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>84</td></tr></table>

RReactive, NR: Nonreactive, BRD : Borderline

The positive agreement was $100 \%$ (84/84) with a $9 5 \%$ exact confidence interval $9 6 . 5 \%$ to $100 \%$ .

# Performance of MONOLISA ™ Anti-HAV EIA in pediatric subjects:

Sixty (60) pediatric samples were tested during the US and European clinical studies inadition to the 39 pediatric samples from acute HAV infection.

Among the US population, 23 had signs and symptoms of hepatitis and 2 were from the high risk group. In the European population, 3 belonged to the general hospitalized population, 22 had signs and symptoms of hepatitis, 2 were from the high risk group, 3 were healthcare workers, 5 had recovered from Hepatitis A infection. The results from these pediatric samples are summarized in the following table.

# BIO RAD

Table 13 : Comparison of Results for MONOLISA™M Anti-HAV EIA versus the comparative assay in the Pediatric European and US Population $( N = 6 0 )$ EY   

<table><tr><td rowspan=2 colspan=1>Subjectcategory</td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparative assay:Borderline</td><td rowspan=1 colspan=3>Comparative assay:Negative</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=2>MONOLISA™M Anti-HAV EIABRD    NR</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIAR    BRD    NR</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIAR    BRD    NR</td></tr><tr><td rowspan=1 colspan=1>EuropeanPediatrics</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>USPediatrics</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>60</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td><td rowspan=1 colspan=1>Negative percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%(29/29)</td><td rowspan=1 colspan=1>90.2 - 100</td><td rowspan=1 colspan=1>96.8%(30/31)</td><td rowspan=1 colspan=1>83.3 - 99.9</td></tr></table>

R: Reactive, NR: Nonreactive, BRD: Borderline

Including the combined US and European Sites, the positive percent agreement of the LA™Anti-HAV A with he coprative antiHAV assay was $9 9 . 5 \%$ (931/936) with a $9 5 \%$ exact confidence interval of $9 8 . 8 \%$ to $9 9 . 8 \%$ . The negative percent agreement of the MONLISAAnti-HAV EIA with the comparative anti-HAV assay was $9 6 . 2 \%$ (378/393) with a $9 5 \%$ exact confidence interval of $9 3 . 8 \%$ to $9 7 . 9 \%$ .

# Study On Vaccinated Subjects:

The HAV antibody response to vaccination was evaluated with 3 different vaccines that are currently licensed in the US: VAQTA® from Merck & Co, HAVRIX® 1440 from Glaxo SmithKline and TWINRIX® from Glaxo SmithKline.

For VAQTA® vaccine, 6 post-vaccination samples from US subjects were available. For HAVRIx® vaccine, 10 matched sets of pre- and post-vaccination samples from European subjects and 8 post-vaccination samples from US subjects were available. For TwINRI® vaccine, 14 matched sets of pre-vaccination and post first dose samples from European individuals were available.

The following results were obtained:

Table 14: MONOLISA™M Anti-HAV EIA Results on Vaccinated Subjects versus the comparative assay - All testing sites   

<table><tr><td rowspan=3 colspan=2></td><td rowspan=1 colspan=3>Comparativeassay:Positive</td><td rowspan=1 colspan=3>Comparative assay:Borderline</td><td rowspan=1 colspan=3>Comparativeassay:Negative</td><td rowspan=3 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIA</td><td rowspan=1 colspan=3>MONOLISA™MAnti- HAV EIA</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV EIA</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=1 colspan=1>VAQTA</td><td rowspan=1 colspan=1>Post-vaccination</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>HAVRIX</td><td rowspan=1 colspan=1>Pre-vaccination</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Post-vaccination</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=2 colspan=1>TWINRIX</td><td rowspan=1 colspan=1>Pre-vaccination</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>Post 1stinjection</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14</td></tr></table>

R : reactive, NR : Nonreactive, BRD : Borderline \* Result close to the cutoff value $( { \mathsf { C O } } / { \mathsf { S } } = 1 . 2 )$

In pre-vaccinatin amples, ONOLAAntiHAVEIA wasin overall agreement w the comparative assay for 21/22 $( 9 5 . 5 \% )$ of samples tested.

For TWINRIX® vaccine on post first dose vaccination, MONOLISA™ Anti-HAV EIA demonstrated reactivity in $9 / 1 4$ $( 6 4 . 3 \% )$ samples. The reference method demonstrated reactivity in 10/14 $( 7 1 . 4 \% )$ samples.

For HAVRIX® post-vaccination samples, MONOLISA™ Anti-HAV EIA demonstrated reactivity in 18/18 $( 1 0 0 \% )$ )samples. The reference method demonstrated reactivity in 18/18 $( 1 0 0 \% )$ samples.

For ${ \mathsf { V A Q T A } } ^ { \otimes }$ post-vaccinationsamples, MONOLISAAnti-HAV EIA demonstrated reactivit $6 / 6 \ ( 1 0 0 \% )$ samples. The reference method demonstrated reactivity in 6/6 $1 0 0 \% )$ samples.

# Seroconversion Panels

Six commercially available HAV seroconversion panels were tested using MONOLISA™M Anti-HAV EIA and the FDA approved comparative assay to determine the sensitivity of the assay. The results are summarized in the following table:

Table 15: MONOLISA ™Anti-HAV EIA Seroconversion Panels Results :   

<table><tr><td rowspan=1 colspan=1>Panel ID</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAV EIA</td><td rowspan=1 colspan=1>Comparative assay</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Post bleed day of firstreactive result</td><td rowspan=1 colspan=1>Post bleed day of firstreactive result</td><td rowspan=1 colspan=1>Difference in Days toReactive result</td></tr><tr><td rowspan=1 colspan=1>07467A</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>60160K</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HAV01</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>RP-004</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>-6</td></tr><tr><td rowspan=1 colspan=1>RP-013</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>PHT902</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td></tr></table>

The sensitivity of the MONOLISA™ Anti-HAV EIA was equivalent to or more sensitive than the comparative assay in the six seroconversion panels tested.

# Cross Reactivity Study

The potential or cross reactivity to otherdisease states, or viruses was evaluated fo the MOLAAni-AVA Assay and he coparativ say.

In addition, samples containingheumatoid factors, auto-antibodies, anti-mouse antibodies were tested.

In total, 255 specimens (including both serum and plasma) from 16 groups of potential crossreactivity were tested. FDA approved methods were used to confirm the disease state of each specimen.

The results are summarized in the following table.

# BIO RAD

Table 16: Potential cross reactivity study   

<table><tr><td rowspan=2 colspan=1>Clinical Condition</td><td rowspan=1 colspan=3>ComparativeassayPositive</td><td rowspan=1 colspan=3>Comparative assayBRD</td><td rowspan=1 colspan=3>Comparative assayNegative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=2>MONOLISATM Anti-HAV EIABRD NR</td><td rowspan=1 colspan=2>AV EIAR  BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=2>MONOLISA™M Anti-HAV EIAR   BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Hepatitis C (HCV)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Hepatitis B (HBV) HBs Ag</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Hepatitis B (HBV) anti HBc</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Human ImmunodeficiencyVirus (HIV)</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus (EBV) IgG</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus (EBV) IgM</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus (CMV) IgG</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus (CMV) IgM</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis IgM</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Mumps IgG</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Varicella Zoster Virus(VZV)IgG</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Varicella Zoster Virus(VZV)IgM</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Anti Nuclear Antibody (ANA)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Human Anti Mouse Antibody(HAMA)</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>255</td></tr></table>

apes weisean:  aciv  MOLntAV A aciv cparativassay HAii

# Precision Study

Within-Laboratory Precision Study :

A 21-member panel was tested: serum samples with the 6 corresponding plasma samples (EDTA K2, EDTA K3, Sodium Citrate, Sodium Heparin, Lithium heparin, ACD) at 3 different levels (1 negative, 1 negative near the cutoff, 1 low positive near the cutoff) were tested on 1 lot, in duplicate, in 2 different runs per day (am and pm), by the same operator for a period of 20 days. The data were analyzed following the CLSI guidance EP5A2. The mean ratio, the Standard Deviation (SD) and percent coefficient of variation (%CV) were calculated for each panel member.

The data summary is shown in the following tables.

Table 17: MONOLISA™M Anti-HAV EIA Precision Results by Panel Member Cutoff to Signal (co/S)   

<table><tr><td>Panel Member</td><td>N</td><td>Mean CO/S</td><td>Within run1 SD</td><td>CV (%)</td><td>Between Run 2 SD</td><td>CV (%)</td><td>Between Day SD</td><td>3 CV</td><td>Total 4 SD CV (%)</td></tr><tr><td>Negative Control CO</td><td>40</td><td>0.282</td><td>NA</td><td>NA</td><td>0.02</td><td>6.4%</td><td>(%) 5.0%</td><td></td><td></td></tr><tr><td>Positive Control C1</td><td>40</td><td>4.093</td><td>NA</td><td>NA</td><td>0.54</td><td>13.5%</td><td>0.01 0.00</td><td>0.02 0.0% 0.49</td><td>8.1% 12.3%</td></tr><tr><td>Serum 1</td><td>80</td><td>0.395</td><td>0.02</td><td>4.1%</td><td>0.03</td><td>6.3% 0.01</td><td>1.9%</td><td>0.03</td><td>7.7%</td></tr><tr><td>EDTA K2 1</td><td>80</td><td>0.379</td><td>0.02</td><td>5.0%</td><td>0.03</td><td>6.8%</td><td>0.01</td><td>1.4% 0.03</td><td>8.6%</td></tr><tr><td>EDTA K3 1</td><td>80</td><td>0.376</td><td>0.01</td><td>3.4%</td><td>0.04</td><td>9.3%</td><td>0.00</td><td>0.0% 0.04</td><td>9.9%</td></tr><tr><td>Sodium Citrate 1</td><td>80</td><td>0.387</td><td>0.04</td><td>10.1%</td><td>0.01</td><td>3.3%</td><td>0.02</td><td>5.1% 0.05</td><td>11.8%</td></tr><tr><td>Sodium Heparin 1</td><td>80</td><td>0.363</td><td>0.01</td><td>3.4%</td><td>0.03</td><td>7.6%</td><td>0.00</td><td>0.0% 0.03</td><td>8.3%</td></tr><tr><td>Lithium Heparin 1</td><td>80</td><td>0.364</td><td>0.01</td><td>3.4%</td><td>0.03</td><td>7.0%</td><td>0.01</td><td>3.5% 0.03</td><td>8.5%</td></tr><tr><td>ACD 1</td><td>80</td><td>0.402</td><td>0.02</td><td>4.3%</td><td>0.04</td><td>10.4%</td><td>0.00</td><td>0.0% 0.05</td><td>11.3%</td></tr><tr><td>Serum 2</td><td>80</td><td>0.691</td><td>0.03</td><td>4.9%</td><td>0.06</td><td>9.6%</td><td>0.01</td><td>2.3% 0.06</td><td>11.0%</td></tr><tr><td>EDTA K2 2</td><td>80</td><td>0.657</td><td>0.02</td><td>3.2%</td><td>0.05</td><td>6.6%</td><td>0.01</td><td>1.8% 0.05</td><td>7.5%</td></tr><tr><td>EDTA K3 2</td><td>80</td><td>0.686</td><td>0.03</td><td>4.9%</td><td>0.06</td><td>8.2%</td><td>0.00 0.0%</td><td>0.07</td><td>9.5%</td></tr><tr><td>Sodium Citrate 2</td><td>80</td><td>0.636</td><td>0.03</td><td>3.7%</td><td>0.05</td><td>7.0%</td><td>0.03 4.8%</td><td>0.06</td><td>9.2%</td></tr><tr><td>Sodium Heparin 2</td><td>80</td><td>0.628</td><td>0.02</td><td>3.1%</td><td>0.04</td><td>6.0%</td><td>0.03</td><td>4.2% 0.06</td><td>7.9%</td></tr><tr><td>Lithium Heparin 2</td><td>80</td><td>0.685</td><td>0.05</td><td>6.6%</td><td>0.06</td><td>8.6%</td><td>0.00</td><td>0.0% 0.08</td><td>10.8%</td></tr><tr><td>ACD 2</td><td>80</td><td>0.746</td><td>0.04</td><td>5.6%</td><td>0.05</td><td>6.4%</td><td>0.03</td><td>4.7% 0.07</td><td>9.7%</td></tr><tr><td>Serum 3</td><td>80</td><td>1.506</td><td>0.06</td><td>4.2%</td><td>0.14</td><td>9.4%</td><td>0.00</td><td>0.4%</td><td>0.15 10.3%</td></tr><tr><td>EDTA K2 3</td><td>80</td><td>1.261</td><td>0.07</td><td>4.7%</td><td>0.11</td><td>7.0%</td><td>0.07</td><td>4.8% 0.15</td><td>9.7%</td></tr><tr><td>EDTA K3 3</td><td>80</td><td>1.257</td><td>0.04</td><td>2.4%</td><td>0.09</td><td>6.0%</td><td>0.05</td><td>3.6% 0.11</td><td>7.4%</td></tr><tr><td>Sodium Citrate 3</td><td>80</td><td>1.462</td><td>0.08</td><td>5.1%</td><td>0.13</td><td>8.7%</td><td>0.07</td><td>4.9% 0.17</td><td>11.2%</td></tr><tr><td>Sodium Heparin 3</td><td>80</td><td>1.380</td><td>0.11</td><td>7.5%</td><td>0.12</td><td>8.0%</td><td>0.05</td><td>3.4% 0.17</td><td>11.4%</td></tr><tr><td>Lithium Heparin 3</td><td>80</td><td>1.346</td><td>0.08</td><td>5.6%</td><td>0.11</td><td>7.1%</td><td>0.03</td><td>1.8% 0.14</td><td>9.2%</td></tr><tr><td>ACD 3</td><td>80</td><td>1.344</td><td>0.05</td><td>3.4%</td><td>0.08</td><td>5.6%</td><td>0.09</td><td>6.0%</td><td>0.13 8.9%</td></tr></table>

NA: Not Applicable l Between Run: variability of the assay performanc from Run to Run Between Day:variability of the assay performance from Day to Day

# Reproducibility Study:

A 6 member panel consisting of diluted plasma specimens (negative and different levels of positive) was tested in triplicate, once a day for 3 days on 3 lots\* of MONOLISA™ Anti-HAV EIA at 3 separate clinical trial sites.Each panel was coded with a different number on each day tested in order to blind the operator to the expected value of the sample.

\*3 different lots were used at the Bio-Rad site and 2 lots were used on each of the externai sites.

The data from all reagent lots and sites were combined to obtain Standard Deviation (SD) and percent coefficient of variation (CV) for within run, between day, between lot, between site and total variance. The data were analyzed according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2005. The PROC GLM procedure in SAS® was used to estimate the variance components of the model. The model was $\curlyvee =$ site $+$ lot (site) $+$ day (lot site) $^ +$ error. The summaries are shown in the following tables.

Table 18: MONOLISA™ Anti-HAV EIA Reproducibility Results by Panel Member Cutof to Signal (CO/S)   

<table><tr><td rowspan="2">Test site</td><td rowspan="2">Panel Member</td><td rowspan="2">N</td><td rowspan="2">Mean CO/S</td><td colspan="2">Within Run1</td><td colspan="2">Between Day^2</td><td colspan="2">Between Lot³</td><td colspan="2">Total4</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td rowspan="6">Site #1</td><td>P1</td><td>18</td><td>0.33</td><td>0.01</td><td>3.03</td><td>0.09</td><td>28.1</td><td>$\fr5}$</td><td>0</td><td>0.09</td><td>28.3</td></tr><tr><td>P2</td><td>18</td><td>0.68</td><td>0.03</td><td>4.9</td><td>0.07</td><td>10.0</td><td>0f}$</td><td>0</td><td>0.07</td><td>11.1</td></tr><tr><td>P3</td><td>18</td><td>1.02</td><td>0.05</td><td>5.0</td><td>0.05</td><td>5.2</td><td>$0fra{5 }$</td><td>4.1</td><td>0.08</td><td>8.3</td></tr><tr><td>P4</td><td>18</td><td>1.98</td><td>0.09</td><td>4.7</td><td>0.32</td><td>16.0</td><td>$0fra5 }$</td><td>0</td><td>0.33</td><td>16.7</td></tr><tr><td>P5</td><td>18</td><td>2.48</td><td>0.18</td><td>7.4</td><td>0.36</td><td>14.8</td><td>05$</td><td>0</td><td>0.41</td><td>16.5</td></tr><tr><td>P6</td><td>18</td><td>3.66</td><td>0.23</td><td>6.2</td><td>0.20</td><td>5.5</td><td>$\fra5 }$</td><td>0</td><td>0.3</td><td>8.3</td></tr><tr><td rowspan="6">Site#2</td><td>P1</td><td>18</td><td>0.35</td><td>0.01</td><td>1.6</td><td>0.02</td><td>4.7</td><td>0.01</td><td>1.2</td><td>0.02</td><td>5.1</td></tr><tr><td>P2</td><td>18</td><td>0.92</td><td>0.03</td><td>3.0</td><td>0.07</td><td>8.0</td><td>$0fr}$</td><td>0</td><td>0.08</td><td>8.5</td></tr><tr><td>P3</td><td>18</td><td>1.28</td><td>0.04</td><td>3.5</td><td>0.00</td><td>0.0</td><td>0.01</td><td>0.62</td><td>0.05</td><td>3.6</td></tr><tr><td>P4</td><td>18</td><td>2.32</td><td>0.08</td><td>3.6</td><td>0.20</td><td>8.5</td><td>0.02</td><td>0.95</td><td>0.21</td><td>9.3</td></tr><tr><td>P5</td><td>18</td><td>3.10</td><td>0.13</td><td>4.1</td><td>0.20</td><td>6.4</td><td>$0fr5}$</td><td>0</td><td>0.23</td><td>7.5</td></tr><tr><td>P6</td><td>18</td><td>4.16</td><td>0.13</td><td>3.2</td><td>0.36</td><td>8.7</td><td>$0\fr5}$</td><td>0</td><td>0.39</td><td>9.3</td></tr><tr><td rowspan="6">Site #3</td><td>P1</td><td>27</td><td>0.36</td><td>0.01</td><td>4.0</td><td>0.02</td><td>5.4</td><td>0.02</td><td>6.6</td><td>0.03</td><td>9.4</td></tr><tr><td>P2</td><td>27</td><td>0.81</td><td>0.03</td><td>3.4</td><td>0.03</td><td>3.9</td><td>0.06</td><td>7.2</td><td>0.07</td><td>8.8</td></tr><tr><td>P3</td><td>27</td><td>1.27</td><td>0.08</td><td>6.6</td><td>0.04</td><td>3.6</td><td>0.14</td><td>11.2</td><td>0.17</td><td>13.5</td></tr><tr><td>P4</td><td>27</td><td>2.16</td><td>0.11</td><td>5.0</td><td>0.05</td><td>2.2</td><td>0.34</td><td>15.7</td><td>0.36</td><td>16.6</td></tr><tr><td>P5</td><td>27</td><td>3.09</td><td>0.11</td><td>3.7</td><td>0.15</td><td>4.9</td><td>0.49</td><td>15.7</td><td>0.52</td><td>16.9</td></tr><tr><td>P6</td><td>27</td><td>4.47</td><td>0.11</td><td>2.5</td><td>0.33</td><td>7.3</td><td>1.01</td><td>22.5</td><td>1.06</td><td>23.8</td></tr></table>

Wu:varbility   assy pefoa fro plicat epl Total : total variability of the assay perormance includes within run, between day and between lot.

Table 19: MONOLISA™ Anti-HAV Reproducibility Summary by Panel Member Cutoff to Signal (CO/S)   

<table><tr><td rowspan="2">Panel Member</td><td rowspan="2">N</td><td rowspan="2">Mean</td><td colspan="2">Within Run1</td><td colspan="2">Between Day2}$</td><td colspan="2">Between Lot3}</td><td colspan="2">Between Siite}$</td><td colspan="2">Total4</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>P1</td><td>63</td><td>0.35</td><td>0.01</td><td>3.2</td><td>0.05</td><td>14.8</td><td>$\fra 5}$</td><td>0</td><td>0.01</td><td>2.9</td><td>0.05</td><td>15.5</td></tr><tr><td>P2</td><td>63</td><td>0.80</td><td>0.03</td><td>3.7</td><td>0.06</td><td>7.12</td><td>0.03</td><td>3.7</td><td>0.11</td><td>13.4</td><td>0.13</td><td>16.0</td></tr><tr><td>P3</td><td>63</td><td>1.20</td><td>0.07</td><td>5.5</td><td>0.04</td><td>3.3</td><td>0.10</td><td>8.6</td><td>0.12</td><td>10.3</td><td>0.18</td><td>14.9</td></tr><tr><td>P4</td><td>63</td><td>2.15</td><td>0.10</td><td>4.5</td><td>0.20</td><td>9.5</td><td>0.22</td><td>10.0</td><td>0.00</td><td>0.0</td><td>0.31</td><td>14.5</td></tr><tr><td>P5</td><td>63</td><td>2.92</td><td>0.14</td><td>4.8</td><td>0.24</td><td>8.3</td><td>0.32</td><td>11.0</td><td>0.25</td><td>8.7</td><td>0.50</td><td>17.0</td></tr><tr><td>P6</td><td>63</td><td>4.15</td><td>0.16</td><td>3.8</td><td>0.31</td><td>7.4</td><td>0.70</td><td>16.9</td><td>$0\fra5 }$</td><td>0</td><td>0.78</td><td>18.9</td></tr></table>

1Withn Run: variability of the assay performance from replicate to replicate Between Day:variabiliy f the assay performance from Day o Day Ben oability he y peoan o Lot  Lo n bil ass p N  l

Reproducibility study on Negative and Positive Controls:

The negative and positive controls were tested in triplicate, once a day by 3 different operators for 3 days. The data were analyzed according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2005.

<table><tr><td rowspan="2">Samples</td><td rowspan="2">N</td><td rowspan="2">Mean</td><td colspan="2">Within Run1</td><td colspan="2">Between Day^2</td><td colspan="2">Between Operator 3</td><td colspan="2">Total4</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>Negative Control</td><td>27</td><td>0.30</td><td>0.01</td><td>2.6</td><td>0.02</td><td>8.3</td><td>$\fra5 }$</td><td>0</td><td>0.03</td><td>8.7</td></tr><tr><td>Positive Control</td><td>27</td><td>4.74</td><td>0.16</td><td>3.5</td><td>0.48</td><td>10.1</td><td>0.07</td><td>1.5</td><td>0.51</td><td>10.8</td></tr></table>

1W :varbility  eassay perforfrom replicat  ele Between Day: variability of the assay performance from Day to Day 3 bl tolvablit y peon nc wihbeay n bewe Op

Manuela Kaul   
RA-Manager   
Bio-Rad France   
3, Boulevard Raymond Poincaré   
92430 Marnes-la-Coquette, France

Re: k063318 Trade/Device Name: MONOLISATM Anti-HAV EIA Regulation Number: 21 CFR 866.3310 Regulation Name: Hepatitis A Virus (HAV) Serological Reagents Regulatory Class: Class II Product Code: LOL Dated: March 21, 2007 Received: April 3, 2007

Dear Ms. Kaul:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassifie i accordance with the provisions f the ederal Fod Dru, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Pleasc be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Devices Evaluation and Safety   
Center for Devices and   
Radiological Health

# INDICATIONS FOR USE STATEMENT

510(k) Number : K 063318

Device Name: MONOLISAT Anti-HAV EIA

# Indications for Use:

The MONOLISA™ Anti-HAV EIA is an in vitro enzyme immunoassay kit intended for use in the qualitative detection of total antibodies (IgG and IgM) to Hepatitis A Virus (anti-HAV) in human adult pediatric) serur plasma TA, Heparin, Cita ACD This kit can e use s an id i he diagnosis of acute or past Hepatitis A Virus (HAV) infection or as an aid in the identification of HAVsusceptible individuals for vaccination. However, any diagnosis should take into consideration the patient's clinical history and symptoms, as well as serological data.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, and cord blood or neonatal specimens.

WARNiNG : This assay is not intended for screening blood or solid or soft tissue donors.

# Office of in Vitro Dlagnostic Device Evaluation and Safety

510d k063318